Johnson & Johnson to start human testing of COVID-19 vaccine next week

Johnson & Johnson's COVID-19 vaccine will begin human testing next week in Belgium, chief scientific officer Paul Stoffels said Thursday. (J&J)

Several biopharma players are racing to deliver COVID-19 vaccines, and now Johnson & Johnson is revving up its plans for late-stage trials earlier than originally expected—and it's aiming far above the FDA's 50% efficacy bar for approval, executives said.

In a conference call Thursday, Johnson & Johnson chief scientific officer Paul Stoffels said the company has seen “strong” preclinical data, and it's now ready to kick off human testing next week.

A phase 1/2a study in more than 1,000 adults ages 18 to 55 will start by enrolling in Belgium next week and open to U.S. participants the week after. The study will also include an arm testing the vaccine in people 65 and older, Stoffels said. Human trials in the Netherlands, Spain, Germany and Japan will follow.

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

From there, J&J expects initial human results in September, and the drugmaker could start phase 3 efficacy testing the same month. “We could have data before the year ends” or early 2021, Stoffels said on Thursday’s call. Vaccinations could begin in early 2021 under that timeline. 

J&J is working with its adenoviral vector platform that allows “rapid” development of new candidates, he told analysts Thursday. The company has already used the platform in RSV, Zika, HIV and Ebola and is confident in its safety profile, the exec said.

J&J's vaccines have already been administered in about 80,000 people, Stoffels said, and J&J's Ebola vaccine won European approval earlier this month.

RELATED: FDA will require 50% efficacy for COVID-19 vaccines. How high is that bar?

In COVID-19, the company's vaccine elicited a “high level of protection” in preclinical studies, Stoffels said, but it's “difficult to extrapolate” how that will play in humans. He said the company is aiming for “significantly above 50%” efficacy, which is the requirement the FDA has set for potential approvals. J&J is instead aiming for 70% or 80% efficacy.

“Let’s hope we reach that, because that could create herd immunity” and “put a stop to the disease,” Stoffels said. An FDA expert recently said herd immunity would require a 70% of the population to receive a vaccine at least 70% effective.

RELATED: Want to defeat COVID-19? Deliver a 70% effective vaccine—and get 70% of people to take it, FDA official says 

At the same time, J&J is building up its manufacturing capacity with partners including Emergent BioSolutions and Catalent, aiming to produce 1 billion doses by the end of next year.

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.